dc.contributor.author | Montero-Melendez, T | en_US |
dc.contributor.author | Gobbetti, T | en_US |
dc.contributor.author | Cooray, SN | en_US |
dc.contributor.author | Jonassen, TEN | en_US |
dc.contributor.author | Perretti, M | en_US |
dc.date.accessioned | 2016-11-29T12:52:21Z | |
dc.date.available | 2015-01-28 | en_US |
dc.date.issued | 2015-04-01 | en_US |
dc.identifier.issn | 0022-1767 | en_US |
dc.identifier.other | 10.4049/jimmunol.1402645 | |
dc.identifier.uri | http://www.jimmunol.org/content/194/7/3381.full.pdf+html | |
dc.identifier.uri | http://qmro.qmul.ac.uk/xmlui/handle/123456789/17994 | |
dc.description.sponsorship | This work was supported by a collaborative project between SynAct Pharma APS and
William Harvey Research Limited | en_US |
dc.format.extent | 3381 - 3388 | en_US |
dc.language.iso | en | en_US |
dc.relation.ispartof | JOURNAL OF IMMUNOLOGY | en_US |
dc.title | Biased Agonism as a Novel Strategy To Harness the Proresolving Properties of Melanocortin Receptors without Eliciting Melanogenic Effects | en_US |
dc.type | Article | |
dc.identifier.doi | 10.4049/jimmunol.1402645 | en_US |
pubs.author-url | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000351663400043&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6a | en_US |
pubs.issue | 7 | en_US |
pubs.notes | Not known | en_US |
pubs.publication-status | Published | en_US |
pubs.volume | 194 | en_US |
qmul.funder | AP1189 as a novel therapeutic for human joint disease: a translational programme of research::Syn Act Pharma APS | en_US |